NIHR MedTech and In Vitro Diagnostic Co-operatives
A new, open competition to designate and fund NIHR MedTech and In Vitro Diagnostic Co-operatives (NIHR MICs) launched 7 November. The scheme will aim to provide NIHR research infrastructure funding of £14m over five years for leading NHS Organisations to act as centres of expertise. NIHR MICs will replace the current NIHR Healthcare Technology Co-operatives and NIHR Diagnostic Evidence Co-operatives but will incorporate and retain the remits of both. Further details can be found on the NIHR MIC page.
Recent competition outcomes
New Biomedical Research Centres: Following an open competition, funding was awarded to 20 NHS and university partnerships across England to host the development of new, ground-breaking treatments, diagnostics, prevention and care for patients in a wide range of diseases like cancer and dementia. On the announcement (14 September 2016), Chief Scientific Advisor Professor Chris Whitty said:
"The future of NHS care depends on the science we do now. This new funding will enable clinical researchers to keep pushing for medical breakthroughs. The NIHR biomedical research centres announced today offer huge potential benefits for patients across the country."
Clinical Research Facilities: Following a competitive application and assessment process, funding has been awarded to 23 NHS organisations to be provided from 1 April 2017 to 31 March 2022. The purpose of the scheme is to provide NIHR funding to meet the necessary recurrent NHS infrastructure costs and NHS Support Costs of funded, world-class, early translational (experimental medicine) research that needs to be undertaken in dedicated, purpose-built CRFs in England, and ensure that funding is targeted appropriately.
Recent closed competitions
Horizon Scanning Research and Intelligence Centre: Applications are closed for the competition to designate and fund a single NIHR Horizon Scanning Research and Intelligence Centre (NIHR HSRIC) in a research active organisation to act as a centre of excellence and notify policy makers of new and emerging health technologies that might require evaluation, and consider clinical and cost impact or modification of clinical guidance typically at around 2-3 years prior to launch on the NHS. Funding will be awarded for a period of five years commencing 1 April 2017 and up to £2 million per annum at current market rates is available for this award.
Patient Safety Translational Research Centres: Applications are closed for the competition for NIHR Patient Safety Translational Research Centre (PSTRC) funding. The scheme aims to provide NIHR research infrastructure funding for leading NHS/University partnerships in England to pull advances from basic research which could be of relevance to patient safety, into early translational, clinical, applied and health services research, which is of relevance to patient safety. Funding of around £14m will be invested, over a five-year period from 1 August 2017, depending on receipt of suitable quality applications.
The Independent Selection Panel Members for the PSTRC competition are:
Professor David Bates (Chair) - Professor of Health Policy and Management at the Harvard School of Public Health, Harvard University.
Margaret Murphy - Member of the steering committee for Patients for Patient Safety, World Health Organisation (WHO) Patient Safety.
Dr Mike Durkin - NHS National Director of Patient Safety, NHS Improvement
Hilary Merrett - Quality and Safety Consultancy, Editor, Clinical Risk
Professor Cordula Wagner - Professor of Patient Safety, Executive Director of the Netherlands Institute of Health Services Research (NIVEL)
Professor Johanna Westbrook - Director, Centre for Health Systems and Safety Research, Australian Institute of Health Innovation, Macquarie University, Sydney, Australia
Professor Maureen Baker - Chair of the Royal College of General Practitioners (on secondment from role as Clinical Director of Patient Safety at NHS HSCIC)
Professor Karina Aase - Professor of Patient Safety, University of Stavanger, Norway